Butterfly Biosciences, Inc. published findings from a deep dig into Cigna's Transparency in Coverage data regarding embryo culture reimbursement in IVF labs.

At Butterfly Bio, We believe every person should have access to effective, affordable gynecologic healthcare solutions. Women's health has been ignored as a niche in medicine and we are fixing that. We are here to help women maintain reproductive health through improved, precision, AI driven pathology assessment reducing average time to diagnosis for gyenecologic issues from > six months to one office visit. Our solutions also empower fertility options by delivering the worlds first non surgical platform for embryo recovery (fertility preservation) and improved IVF with visual embryo transfer. With our devices, physicans get improved tools for diagnostics and fertility. We offer a new, less invasive alternative to diagnostics and fertility treatments that provides more access, comfort and convenience. Everyone deserves the opportunity to live free of gynecologic pain, and maintain fertility to achieve their dreams of parenthood. In our efforts to discover and democratize a lavage-based, lower cost and higher precision diagnostics and fertility care we see the chance to reimagine a higher quality, less invasive and more easily accessable gynecologic health experience. We chose butterfly as our company name because our goal is transformation; with our technology we believe we can change the experience of fertility care to something more natural, affordable, easier to experience and accessible to all who need it. Butterfly Biosciences: Fertility care for all.